血清异常凝血酶原在肝细胞癌诊疗中的意义

孙玉; 张洪海; 袁春旺; 扈彩霞; 刘博君; 崔石昌; 钱智玲; 张英华; 张永宏; 郑加生

doi:10.3969/j.issn.1001-5256.2018.10.017

血清异常凝血酶原在肝细胞癌诊疗中的意义

DOI: 10.3969/j.issn.1001-5256.2018.10.017

首都医科大学附属北京佑安医院肿瘤微创介入中心

基金项目:

国家自然科学基金资助项目(81472328)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2471
- HTML全文浏览量: 44
- PDF下载量: 400
- 被引次数: 0
出版历程
- 出版日期: 2018-10-20

Value of serum des-γ-carboxy-prothrombin in the diagnosis and treatment of hepatocellular carcinoma

Minimally Invasive Interventional Center of Oncology, Beijing YouAn Hospital, Capital Medical University

Research funding:

摘要

摘要: 目的研究血清异常凝血酶原（DCP）在肝细胞癌（HCC）患者中的表达水平及其与肿瘤性状、病理及临床特征之间的关系。方法选择2016年1月-2018年3月在首都医科大学附属北京佑安医院住院治疗并经外科手术切除组织病理确诊的肝细胞癌患者80例,检测患者术前血清DCP及AFP水平并进行相关性分析,分析患者的临床信息、影像学、病理学结果与DCP水平的关系。计量资料两组间比较采用Mann-Whitney U检验,多组间比较采用Kruskal-Wallis H检验,进一步两两比较采用Mann-Whitney U检验,两组样本的相关性检验采用Spearman相关分析。结果 HCC患者血清AFP与DCP水平无明显相关性（r=0. 141,P>0. 05）; HCC患者血清DCP水平与肿瘤直径之间显著相关（r=0. 563,P <0. 01）;肝内多发肿瘤、合并远处转移、存在肉眼或微观血管侵犯的HCC患者血清DCP水平分别高于肝内单发肿瘤（Z=-5. 484,P <0. 001）、无远处转移（Z=-4. 569,P <0. 001）、无肉眼血管侵犯（Z=-3. 713,P <...
- 癌,肝细胞 /
- 异常凝血酶原 /
- 甲胎蛋白类
Abstract: Objective To investigate the expression of des-γ-carboxy-prothrombin ( DCP) in serum in hepatocellular carcinoma ( HCC) patients and its association with tumor properties, pathology, and clinical features. Methods A total of 80 patients who were hospitalized and treated in our hospital from January 2016 to March 2018 and were diagnosed with HCC by pathology after surgical resection were enrolled. The serum levels of DCP and alpha-fetoprotein ( AFP) were measured before surgery and the correlation between them was analyzed. The association of DCP level with clinical data, imaging findings, and pathological results was analyzed. Mann-Whitney U test was used for comparison of continuous data between two groups, Kruskal-Wallis H test was used for comparison between multiple groups, and the Mann-Whitney U test was used for further comparison between two groups; the Spearman correlation analysis was performed to investigate correlation. Results There was no significant correlation between the serum levels of AFP and DCP in HCC patients ( r = 0. 141, P >0. 05) . In HCC patients, serum DCP level was significantly correlated with tumor diameter ( r = 0. 563, P < 0. 01) . The HCC patients with intrahepatic multiple tumors, distant metastasis, or macrovascular or microvascular invasion had a significantly higher serum DCP level than those with intrahepatic single tumor ( Z =-5. 484, P < 0. 001) or without distant metastasis ( Z =-4. 569, P < 0. 001) , macrovascular invasion ( Z =-3. 713, P < 0. 001) , or microvascular invasion ( Z =-3. 244, P = 0. 001) . According to the staging criteria in China, the patients with stage Ⅰ HCC had a significantly lower serum DCP level than those with stage Ⅱ/Ⅲ HCC ( P = 0. 005 and P < 0. 001) , while there was no significant difference in serum DCP level between the patients with stage Ⅱ HCC and those with stage Ⅲ HCC ( P = 0. 477) .The patients with Edmondson-Steiner grade Ⅱ/Ⅲ HCC had a significantly lower serum DCP level than those with Edmondson-Steiner grade IV HCC ( P < 0. 001 and P = 0. 002) , while there was no significant difference in serum DCP level between the patients with Edmondson-Steiner grade Ⅱ HCC and those with Edmondson-Steiner grade Ⅲ HCC ( P = 0. 133) . Conclusion In HCC patients, serum DCP level is associated with number of tumors, tumor size, clinical stage, distant metastasis, vascular invasion, and pathological grade.
- carcinoma, hepatocellular /
- des-γ-carboxy-prothrombin /
- alpha-fetoproteins

HTML全文

参考文献(18)

[1]PETRUZZIELLO A.Epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) related hepatocellular carcinoma[J].Open Virol J, 2018, 12:26-32.

[2]EMOKPAE MA, ADEJUMOL BG, ABDU A, et al.Serum alphafetoprotein level is higher in hepatitis C than hepatitis B infected chronic liver disease patients[J].Niger Med J, 2013, 54 (6) :426-429.

[3]National Health and Family Planning Commission of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V 2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.

[4] LIEBMAN HA, FURIE BC, TONG MJ, et al.Des-gammacarboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma[J].N Engl J Med, 1984, 310 (22) :1427-1431.

[5]BAEK YH, LEE JH, JANG JS, et al.Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP[J].Hepatogastroenterology, 2009, 56 (91-92) :763-767.

[6]GIANNELLI G, ANTONACI S.New frontiers in biomarkers for hepatocellular carcinoma[J].Dig Liver Dis, 2006, 38 (11) :854-859.

[7]SHIMADA M, YONEMURA Y, IJICHI H, et al.Living donor liver transplantation for hepatocellular carcinoma:A special reference to a preoperative des-gamma-carboxy prothrombin value[J].Transplant Proc, 2005, 37 (2) :1177-1179.

[8]MIYAAKI H, NAKASHIMA O, KUROGI M, et al.Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis:A histopathological study of surgically resected hepatocellular carcinoma[J].J Gastroenterol, 2007, 42 (12) :962-968.

[9]GOTOH M, NAKATANI T, MASUDA T, et al.Prediction of invasive activities in hepatocellular carcinomas with special reference to alphafetoprotein and des-gamma-carboxyprothrombin[J].Jpn J Clin Oncol, 2003, 33 (10) :522-526.

[10]HAGIWARA S, KUDO M, KAWASAKI T, et al.Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma[J].JGastroenterol, 2006, 41 (12) :1214-1219.

[11]ZAKHARY NI, KHODEER SM, SHAFIK HE, et al.Impact of PIVKA-II in diagnosis of hepatocellular carcinoma[J].J Adv Res, 2013, 4 (6) :539-546.

[12]DURAZO FA, BLATT LM, COREY WG, et al.Des-gammacarboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma[J].JGastroenterol Hepatol, 2008, 23 (10) :1541-1548.

[13]BAE HM, LEE JH, YOON JH, et al.Protein induced by vitamin Kabsence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma:a prospective evaluation[J].BMC Cancer, 2011, 11:435.

[14]CARR BI, KANKE F, WISE M, et al.Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gammacarboxy prothrombin in histologically proven hepatocellular carcinoma in the United States[J].Dig Dis Sci, 2007, 52 (3) :776-782.

[15]PARK MS, LEE KW, KIM H, et al.Usefulness of PIVKA-II after living-donor liver transplantation for hepatocellular carcinoma[J].Transplant Proc, 2017, 49 (5) :1109-1113.

[16]UEDA N, SHIRAHA H, FUJIKAWA T, et al.Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines[J].Mol Oncol, 2008, 2 (3) :241-249.

[17]FUJIKAWA T1, SHIRAHA H, UEDA N, et al.Des-gammacarboxyl prothrombin-promoted vascular endothelial cell proliferation and migration[J].J Biol Chem, 2007, 282 (12) :8741-8742.

[18] QIN X, TANG G, GAO R, et al.A multicenter study on PIVKAreference interval of healthy population and establishment of PIVKAcutoff value for hepatocellular carcinoma diagnosis in China[J].Int J Lab Hematol, 2017, 39 (4) :392-401.

施引文献

资源附件(0)

访问统计